Fat tissue secrets: could semaglutide protect kidneys?

NCT ID NCT07187830

Recruiting now Knowledge-focused Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how semaglutide, a drug used for diabetes and weight loss, changes fat tissue around the kidneys, heart, and liver in people with type 2 diabetes and chronic kidney disease. Researchers will compare patients taking semaglutide to those not taking it. The goal is to understand how these fat changes relate to kidney and liver health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this could help doctors understand how semaglutide improves kidney and liver health by targeting fat tissue.
What could go wrong: This is a small, early-stage observational study, not a large treatment trial. It may not prove that semaglutide directly causes the changes seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease chronic renal failure syndrome diabetes mellitus diabetic kidney disease fatty liver disease Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES OBESITY & OVERWEIGHT

Contacts and locations

Show contact details

Locations

Mazankowski Alberta Heart Institute
RECRUITING

Edmonton, Alberta, T6G 2B7, Canada

Contact Email: •••••@•••••

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.